Moclobemide in the treatment of social phobia

@article{Nutt1996MoclobemideIT,
  title={Moclobemide in the treatment of social phobia},
  author={David J. Nutt and S. A. Montgomery},
  journal={International Clinical Psychopharmacology},
  year={1996},
  volume={11},
  pages={77-82}
}
Social phobia is a common disorder which is associated with considerable suffering and impairment. Effective treatments have now been developed and they represent an important advance in the management of the disorder. Moclobemide is a reversible inhibitor of monoamine oxidase A (RIMA) which has an established place in the treatment of depression. The efficacy of moclobemide in social phobia has been demonstrated in short-term treatment for up to 12 weeks in three placebocontrolled studies. It… Expand
Social phobia: diagnosis, severity and implications for treatment
  • S. Montgomery
  • Psychology, Medicine
  • European Archives of Psychiatry and Clinical Neuroscience
  • 1999
TLDR
Effective treatment of social phobia appears to be able to overcome the substantial chronicity of illness which is frequent in sufferers. Expand
Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder
TLDR
In a large sample of social anxiety disorder patients with and without comorbid anxiety disorders, moclobemide was both effective and well-tolerated in the short as well as long-term, and strengthen the range of therapeutic options for managing this important disorder. Expand
Moclobemide and cognitive behavioral therapy in the treatment of social phobia. A six-month controlled study and 24 months follow up.
TLDR
In patients with a generalized form of social phobia, CBT was the best choice for reduction of avoidant behavior while a reduction of subjective general anxiety appeared later than in moclobemide, and after 6 months of treatment there were best results reached in groups treated with CBT and there was no advantage of the combined treatment. Expand
Social Anxiety Disorder - A Review of Pharmacological Treatments
Social anxiety disorder (social phobia, SAnD) is a chronic, impairing disorder characterised by embarrassment and fear relat- ing to public scrutiny and social performance. In its generalised form itExpand
Social phobia: diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment.
TLDR
The first, large scale, placebo-controlled study to assess the efficacy of drug treatment in generalized social phobia has been completed with paroxetine, which was more effective in reducing the symptoms than placebo and was well tolerated. Expand
The placebo response in social phobia
TLDR
In social phobia, the placebo effect has turned out to be moderately large and has shown no increase over the past decade, and the most discriminative results are probably to be expected in a sample of patients who are moderately to severely impaired. Expand
A 2010 Evidence-Based Algorithm for the Pharmacotherapy of Social Anxiety Disorder
TLDR
The updated algorithm attempts to summarize succinctly the recent literature in this area, as well as to include the views of an international panel of experts with diverse experience on the pharmacotherapy of social anxiety disorder. Expand
Kombinationstherapie bei Angststörungen: Aktuelle Datenlage und Empfehlungen für den klinischen Alltag
Combined Therapy in Anxiety Disorders: Current Data and Recommendations for the Clinical Practice Method:Over the past couple of years there has been a definite increase in studies on the effects ofExpand
Moclobemide : An Update of its Pharmacological Properties and Therapeutic Use.
TLDR
Comparative studies have established that moclobemide is better tolerated at therapeutic dosages and has less toxicity in overdose than TCAs and nonselective, irreversible MAO inhibitors, and is also effective in patients with a primary diagnosis of social phobia. Expand
Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects
TLDR
The maximum tolerated dose of moclobemide in healthy subjects is 600”mg b.i.d. provided the tyramine content in a meal is not higher than 50 mg, and the incidence and intensity of adverse events was dose-dependent. Expand
...
1
2
...